Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Welcome and Introduction to Vi3C

Opening Session Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Sep
10
Today In Oncology
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo